Bellevue Group AG Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001674546

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q4 2025 · 176 positions · Total reported value $5.28B · Top-10 concentration 49.5% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 61.0% · 17 new · 64 cut · 24 exited

Active Share (vs S&P 500): 94.1% · vs QQQ: 96.5% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +12.4% · vs SPY -2.4% · Prev Value $4.20B — last quarter positions weighted by this quarter price moves · ranking

In its Q4 2025 13F filing, Bellevue Group AG disclosed 176 equity positions with a combined reported value of $5.28B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 49.5% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q4 2025 were RVMD ($398.71M), ARGX ($388.40M), IONS ($379.90M). By sector, the heaviest allocations are Health Care 88.5%, Industrials 1.7%. Versus the prior quarter, allocation shifted toward Other (+3.5pp) and away from Health Care (-3.3pp).

Versus the prior quarter, Bellevue Group AG opened 17 new positions, trimmed 64 and fully exited 24, a turnover rate of 61.0% of positions. The portfolio's overlap with the prior quarter was 75% of names.

The largest new positions opened in Q4 2025 were FOLD ($152.87M), VRDN ($135.64M), NUVL ($104.36M).

Of the 24 positions fully exited versus the prior quarter, the largest were AGIO ($149.11M), AKRO ($113.44M), BHVN ($42.07M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q4 2025)

  • FOLD AMICUS THERAPEUTICS INC · $152.87M
  • VRDN VIRIDIAN THERAPEUTICS INC · $135.64M
  • NUVL NUVALENT INC · $104.36M
  • VERA VERA THERAPEUTICS INC · $85.99M
  • JBIO JADE BIOSCIENCES INC · $51.55M
  • MAZE MAZE THERAPEUTICS INC COM · $36.78M
  • TNGX TANGO THERAPEUTICS INC · $34.80M
  • MDLN MEDLINE INC · $4.94M

Fully Exited (vs previous quarter)

  • AGIO AGIOS PHARMACEUTICALS INC · prev qtr: $149.11M
  • AKRO AKERO THERAPEUTICS INC · prev qtr: $113.44M
  • BHVN BIOHAVEN LTD · prev qtr: $42.07M
  • HOLX HOLOGIC INC · prev qtr: $16.73M
  • MGNX MACROGENICS INC · prev qtr: $16.67M
  • BAX BAXTER INTL INC · prev qtr: $1.55M
  • BIDU BAIDU INC · prev qtr: $263.54K
  • MLTX MOONLAKE IMMUNOTHERAPEUTICS · prev qtr: $251.32K

Insider Transactions (Form 4)

Latest Bellevue Group AG buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Bellevue Group AG files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 148 positions worth $4.75B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Portfolio Structure

  • 148 positions · $4.75B reported value (Q2 2026)
  • Top 10 holdings = 42.9% of reported value
  • Largest position: AMGN (AMGEN INC) at 6.5%
  • Average position size: $32.11M

Sector Tilt

  • Health Care 92.6%
  • Industrials 1.7%
  • Information Technology 0.4%
  • (classified holdings cover 95% of value)

Quarterly Activity

  • Q2 2026: 17 new, 39 added, 64 reduced, 24 exited
  • 28 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 5.01M $398.71M 7.56%
7.56%
Reduce
2 461.85K $388.40M 7.36%
7.36%
Reduce
3 4.80M $379.90M 7.20%
7.20%
Reduce
4 681.12K $308.79M 5.85%
5.85%
Add
5 1.70M $241.58M 4.58%
4.58%
Reduce
6 2.63M $189.77M 3.60%
3.60%
Add
7 322.03K $182.38M 3.46%
3.46%
Reduce
8 4.06M $178.69M 3.39%
3.39%
Add
9 445.90K $177.31M 3.36%
3.36%
Hold
10 1.32M $165.00M 3.13%
3.13%
Reduce
11 10.74M $152.87M 2.90%
2.90%
New
12 1.56M $148.71M 2.82%
2.82%
Reduce
13 4.36M $135.64M 2.57%
2.57%
New
14 360.58K $126.73M 2.40%
2.40%
Reduce
15 1.04M $104.36M 1.98%
1.98%
New
16 410.32K $101.16M 1.92%
1.92%
Add
17 3.62M $98.26M 1.86%
1.86%
Add
18 2.80M $97.08M 1.84%
1.84%
Hold
19 1.04M $88.92M 1.69%
1.69%
Add
20 1.70M $85.99M 1.63%
1.63%
New
21 766.59K $73.64M 1.40%
1.40%
Add
22 8.35M $70.60M 1.34%
1.34%
Hold
23 94.54K $63.96M 1.21%
1.21%
Add
24 175.17K $57.83M 1.10%
1.10%
Add
25 847.40K $56.24M 1.07%
1.07%
Add
26 186.70K $53.07M 1.01%
1.01%
Reduce
27 265.66K $51.56M 0.98%
0.98%
Reduce
28 3.34M $51.55M 0.98%
0.98%
New
29 194.63K $44.56M 0.84%
0.84%
Add
30 135.40K $42.10M 0.80%
0.80%
Reduce
31 161.21K $38.83M 0.74%
0.74%
Reduce
32 1.53M $37.93M 0.72%
0.72%
Reduce
33 65.08K $37.71M 0.71%
0.71%
Reduce
34 887.71K $36.78M 0.70%
0.70%
New
35 34.00K $36.54M 0.69%
0.69%
Reduce
36 424.51K $34.82M 0.66%
0.66%
Reduce
37 3.93M $34.80M 0.66%
0.66%
New
38 134.86K $30.81M 0.58%
0.58%
Reduce
39 110.01K $30.28M 0.57%
0.57%
Reduce
40 261.94K $29.58M 0.56%
0.56%
Add
41 126.80K $26.24M 0.50%
0.50%
Add
42 5.16M $25.89M 0.49%
0.49%
Hold
43 101.70K $25.78M 0.49%
0.49%
Reduce
44 1.49M $25.34M 0.48%
0.48%
Reduce
45 69.64K $24.41M 0.46%
0.46%
Reduce
46 291.96K $23.93M 0.45%
0.45%
Hold
47 262.68K $22.93M 0.43%
0.43%
Reduce
48 141.47K $22.09M 0.42%
0.42%
Reduce
49 238.68K $21.46M 0.41%
0.41%
Reduce
50 25.10K $20.59M 0.39%
0.39%
Reduce

FAQ

What did Bellevue Group AG buy in 2025-Q4?

In its 2025-Q4 13F filing, Bellevue Group AG reported 176 equity positions worth $5.28B in aggregate; its largest disclosed positions were RVMD ($398.71M), ARGX ($388.40M), IONS ($379.90M).

How large is Bellevue Group AG's portfolio?

Bellevue Group AG reported $5.28B of long equity holdings across 176 positions as of 2025-Q4. Top-10 holdings account for 49.5% of reported value.

What is Bellevue Group AG's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/bellevue-group-ag/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →